3-trimethoxysilylpropylurea

We are 3-trimethoxysilylpropylurea CAS:23843-64-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Chemical Name:3-trimethoxysilylpropylurea
CAS.NO:23843-64-3
Synonyms:(3-Ureidopropyl)trimethoxysilane; 1-[3-(TriMethoxysilyl)propyl]urea; 3-ureidopropyl trimethoxysilane; N-[3-(trimethoxysilyl)propyl]urea;
Molecular Formula:C7H18N2O4Si
Molecular Weight:222.31400
 
Physical and Chemical Properties:
Density:1.15;
Boiling point:217-250^oC;
Flash point:99^oC;
Index of Refraction:1.46;
 
Specification:
Appearance:Amber clear liquid
Purity(GC):≥98.0%
 
Packing:220 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Ureido-functional silane has beter stability than aminosilanes in reactive polymer systems, like phenolic, epoxy, urea-melamine or polyurethane.
Ureido-functional silane does not generate color with time and aging.
Ureido-functional silane provides nitrogen reactivity without tyoical aminosilanes strong basic characteristics.
Ureido-functional silane has good adhesive and sealant adhesion to oil metals.
It can improve adhesion between the inorganic fler or fiber and the polymer.
It can be used for glass fiber sizes and finishes, wool insulation resin binders, numerous primers, foundry sand binders, adhesives, sealants and abrasive grinding wheel binders.




Related News: If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.2-(chloromethoxy)propane If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.120739-77-7 If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.1-Heptanethiol At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.